These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26503996)

  • 61. [A long-term survival case with multiple liver metastases from duodenal gastrointestinal stromal tumor that was drastically reduced by the treatment with imatinib].
    Sakakura C; Miyagawa K; Fukuda K; Kin S; Nakase Y; Kuriu Y; Nakashima S; Yoshikawa T; Yamaoka N; Sagara Y; Hagiwara A; Yamagishi H
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1739-41. PubMed ID: 16315926
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib.
    Vij M; Patra S; Rela M
    Indian J Pathol Microbiol; 2013; 56(3):291-3. PubMed ID: 24152514
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The economic impact of cytoreductive surgery and tyrosine kinase inhibitor therapy in the treatment of advanced gastrointestinal stromal tumours: a Markov chain decision analysis.
    Look Hong NJ; Chang SL; Raut CP
    Eur J Cancer; 2014 Jan; 50(2):397-405. PubMed ID: 24215847
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
    Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
    J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour.
    Cananzi FC; Belgaumkar A; Lorenzi B; Mudan S
    ANZ J Surg; 2014 Dec; 84(12):937-42. PubMed ID: 25444423
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review.
    Feng M; Yang Y; Liao W; Li Q
    Front Public Health; 2021; 9():768765. PubMed ID: 35083189
    [No Abstract]   [Full Text] [Related]  

  • 67. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
    Teng JF; Mabasa VH; Ensom MH
    Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A metastatic case of gastrointestinal stromal tumor (GIST) treated with imatinib mesylate (Glivec(®)) in Mali.
    Diallo DA; Ly M; Diallo G; Dembélé AK; Touré M; Touré BA; Koné A; Sidibé S; Dembelé M; Traore BC
    Clin Res Hepatol Gastroenterol; 2011 Oct; 35(10):675-7. PubMed ID: 21641899
    [TBL] [Abstract][Full Text] [Related]  

  • 69. 'Time is a GIFT in GIST'--the medical and paramedical perspective of a case with metastatic gastrointestinal stromal tumor.
    Sevinc A; Camci C
    Chemotherapy; 2009; 55(1):11-4. PubMed ID: 18974643
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Imatinib in the GIST therapy: ten years later].
    Lopez M
    Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor.
    Wu X; Li J; Zhou Y; Mao Y; Luo S; He X; Wang L; Shen Y; Zhang H; Yang L; Zhang J
    Chemotherapy; 2018; 63(6):301-307. PubMed ID: 30836365
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Targeted therapy combined with immunotherapy in gastrointestinal stromal tumor: a new era of hope and challenges].
    Zhao W; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):966-971. PubMed ID: 28900984
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era.
    van der Graaf WTA; Tielen R; Bonenkamp JJ; Lemmens V; Verhoeven RHA; de Wilt JHW
    Br J Surg; 2018 Jul; 105(8):1020-1027. PubMed ID: 29664995
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Imatinib induces ferroptosis in gastrointestinal stromal tumors by promoting STUB1-mediated GPX4 ubiquitination.
    Sun X; Zhang Q; Lin X; Shu P; Gao X; Shen K
    Cell Death Dis; 2023 Dec; 14(12):839. PubMed ID: 38110356
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Fear of progression in patients with gastrointestinal stromal tumors (GIST): Is extended lifetime related to the Sword of Damocles?
    Custers JA; Tielen R; Prins JB; de Wilt JH; Gielissen MF; van der Graaf WT
    Acta Oncol; 2015; 54(8):1202-8. PubMed ID: 25734906
    [TBL] [Abstract][Full Text] [Related]  

  • 76. GIST: Institutional Experience at SRMS-IMS, India.
    Gupta S; Amit K; Gupta A; Argawal T
    Gulf J Oncolog; 2016 Sep; 1(22):64-6. PubMed ID: 28191810
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors].
    Qiu H; Zhuang W; Wang X; Huang M; Zhou Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1031-1034. PubMed ID: 28900995
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Subdural hematoma in a patient taking imatinib for GIST: a case report and discussion of risk with other chemotherapeutics.
    Theodotou CB; Shah AH; Ivan ME; Komotar RJ
    Anticancer Drugs; 2016 Mar; 27(3):259-63. PubMed ID: 26628484
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A case of gene mutation responsible for GIST drug resistance.
    Wan X; Li L; Zhang Y
    Asian J Surg; 2023 Dec; 46(12):5830-5831. PubMed ID: 37661476
    [No Abstract]   [Full Text] [Related]  

  • 80. Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST.
    Teranishi R; Takahashi T; Nishida T; Kurokawa Y; Nakajima K; Koh M; Nishigaki T; Saito T; Yamamoto K; Yamashita K; Tanaka K; Makino T; Motoori M; Omori T; Hirota S; Hayashi Y; Takehara T; Eguchi H; Doki Y
    Int J Clin Oncol; 2023 May; 28(5):680-687. PubMed ID: 36971916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.